Navigation Links
Gene information predicts survival time, possible new treatment options for lung-cancer patients
Date:12/14/2010

DALLAS Dec. 14, 2010 Researchers at UT Southwestern Medical Center have discovered sets of genes active in cancer cells and normal tissue that predict survival time and potential new treatments for patients with non-small cell lung cancer.

"Patient responses to cancer treatment vary widely and often depend on subtle biological differences among tumors," said Dr. David Mangelsdorf, chairman of pharmacology at UT Southwestern and co-lead author of the study, published Dec. 14 by PLoS Medicine.

"These findings are important because the ability to determine which genes are being expressed in each person's tumor, as well as a patient's likely survival time, can guide physicians to the most effective and appropriate personalized treatments," he said.

Researchers involved in the study at UT Southwestern and UT M.D. Anderson Cancer Center carefully microdissected lung tumors and adjacent healthy lung tissue from 30 patients. To determine which genes were active, they examined each sample for the presence of messenger ribonucleic acid (mRNA) associated with the 48 known genes for molecules called nuclear hormone receptors.

The research team then compared the set of active genes, also called a gene expression profile or gene signature, with the actual clinical outcome of each study patient. They found that the expression of genes for specific nuclear hormone receptors was an excellent predictor of which patients were likely to survive the longest. They validated their test by screening more than 500 additional lung-tumor samples and accurately predicting those patients' outcomes.

In particular, the presence of two nuclear receptors the short heterodimer partner (SHP) and the progesterone receptor (PR) in tumor tissue was predictive of a good prognosis. Patients with those so-called biomarkers in their cancer cells lived the longest.

In normal lung tissue, a good prognosis was associated with the presence of nuclear receptors called nerve growth factor induced gene B3 (NGFIB3) and mineralocorticoid receptor (MR).

Dr. Mangelsdorf, a National Academy of Sciences member who is a leading expert on nuclear receptors, said the investigators focused on screening for the activity of these 48 nuclear receptor genes because several of them are known to be involved in promoting or inhibiting cancer. In addition, drugs that target certain nuclear receptors already are being used as front-line therapy in humans against breast cancer, prostate cancer and acute leukemia.

"The goal of identifying these genetic signatures in lung cancer is not just to determine how long a cancer patient will live, but also to home in on the most relevant drug or therapy targets that act specifically on these particular gene products," said Dr. Mangelsdorf, who also is an investigator with the Howard Hughes Medical Institute.

The results are a significant step toward personalized medicine, said Dr. John Minna, director of the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and the W.A. "Tex" and Deborah Moncrief Jr. Center for Cancer Genetics who has been investigating the biology of lung cancer for more than 30 years.

"Our long-term goal is to be able to sample a patient's lung cancer and perform molecular tests that can predict both how a patient will do and, more importantly, the best treatment for that individual," said Dr. Minna, co-lead author of the study.

"We were amazed to find that the pattern of expression of nuclear receptors in both lung cancers and normal lung tissue were so predictive of a patient's outcome. Because available drugs already target so many of these receptors, our next step is to find out which drugs will kill lung cancer cells expressing these specific receptors."


'/>"/>

Contact: Amanda Siegfried
amanda.siegfried@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. New survey device gets better information on teenage sexual behavior
2. Quantifying fragmentation of medical information
3. Health information technology is focus of AAP symposium
4. Circulating tumor cells can provide real-time information on patients current disease state
5. Nationwide Health Information Network now carries public health data
6. Benefits of increased health care transparency hinge on reliable and valid information, says ACP
7. What can health-care facilities do to help patients better understand medical information
8. Input-output trade-offs found in human information processing
9. Primary care doctors get little information about chronic sinusitis
10. Prosthesis with information at its fingertips
11. Anakam And Axolotl Collaborate To Deliver A Multi-Factor Authentication Platform For Santa Cruz Health Information Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/21/2017)... , ... April 21, 2017 , ... An April 10 ... a pair of ancient teeth, which reveal a great deal about prehistoric ice-age dental ... sharp stone may have been used to remove decayed dental matter, and that teeth ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. ... osteoma is a benign bony lump located on the forehead usually attributed to a ... with sight and pain. Dr. Shah has discovered an approach that is minimally invasive. ...
(Date:4/21/2017)... ... 21, 2017 , ... Dudnyk has announced the launch of its new brand ... full potential of specialty and orphan brands can only be achieved when the needs ... Unifying Effect is at the heart of a true partnership between our agency and ...
(Date:4/21/2017)... ... , ... The Hong Kong Polytechnic University (PolyU) launched today the University Research ... in Hong Kong to support teaching, learning and research. It is also the largest ... in Hong Kong. , With an area of 620 square metres and more ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology: